Consensus on anti-platelet therapy in peripheral arterial disease: Saving lives and limbs

Platelets

Volumn 14, Issue 7-8, 2003, Pages 403-406

  Donnelly, Richard ^a   Collinson, Deborah J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIOPLASTY; ANKLE PRESSURE; ARTERY DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BYPASS SURGERY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS; DIABETES MELLITUS; DIAPHRAGM MUSCLE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; GANGRENE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GOOD CLINICAL PRACTICE; HIGH RISK POPULATION; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVASCULARIZATION; SIDE EFFECT; SURVIVAL RATE; VASCULAR DISEASE;

ARTERIOSCLEROSIS; ASPIRIN; CONSENSUS; DIABETES COMPLICATIONS; DIPYRIDAMOLE; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; TICLOPIDINE;

EID: 0346672406     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100310001632603     Document Type: Editorial

References (26)

1. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.
2. Newman A, Tyrrel K, Kuller L. Mortality over 4 years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 1997; 45: 1472-8.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
4. Disease Analyser - MediPlus database. London: IMS Health, 2002.
5. Donnelly R, Yeung J M C. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg 2002; 23: 100-7.
6. Peripheral Arterial Disease Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease: Consensus statement. Eur J Vasc Endovasc Surg 2003; 26: 1-16.
7. Fowkes FGR, Housley E, Cawood E H, Macintyre C C, Ruckley C V, Prescott R J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-92.
8. Vascular Surgical Society of G B and Ireland. Critical limb ischaemia: management and outcome. Report of a national survey. Eur J Vasc Endovasc Surg 1995; 10: 108-13.
9. Hart W M, Guest J F. Critical limb ischaemia: the burden of illness in the UK. Br J Med Econ 1995; 8: 211-21.
10. Brewster D C, Lasalle A J, Robinson J G, Strayhorn E C, Darling C. Femoro-popliteal graft failures. Arch Surg 1983; 118: 1043-7.
11. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation 1984; 70: 619-23.
12. Burns P, Gough S, Bradbury A W. Management of peripheral arterial disease in primary care. Br Med J 2003; 326: 584-8.
13. Murphy M K, Black N A, Lampling D L, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: 1-8.
14. Aronow W S, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease and atherothrombotic brain infarction in men and women > 62 years of age. Am J Cardiol 1994; 74: 64-5.
15. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
16. Robless P, Mikhailidis D P, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
17. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
18. Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischaemic events. Diabetes Care 2003; 26: 2181-8.
19. Popma J, Ohman E, Weitz J, Lincoff A, Harrington R, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: S321-36.
20. Watson H, Belcher G, Horrocks M. Adjuvant medical therapy in peripheral bypass surgery. Br J Surg 1999; 86: 981-91.
21. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159-68.
22. Tangelder M, Lawson J, Algra A, Eikelboom B. Systematic review of randomised controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischaemic events after infrainguinal bypass surgery. J Vasc Surg 1999; 30: 701-9.
23. Girolami B, Bernardi E, Prins M, et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000; 19: 370-80.
24. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 2000; 355: 346-51.
25. Smout J, Stansby G. Aspirin resistance. Br J Surg 2002; 89: 4-5.
26. Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.